Ausgabe 4/2022
Inhalt (24 Artikel)
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy
Shahd M. Hassona, Entsar A. Saad, Hala A. Kiwan, Mohamed M. Hassanien
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA
Wenting Chen, Chenxin Qie, Xinlei Hu, Lanlan Wang, Jingwei Jiang, Wanmei Liu, Jun Liu
The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines
Markus Haas, Teresa Lenz, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J Jank
Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells
Wei Chi, Lianyong Zhang, Xue Wang, Jingjing Li, Fei Li, Yuxia Ma, Qianyun Zhang
Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia
Chie Ishikawa, Naoki Mori
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells
Jean Carlos Lipreri da Silva, Maria Fernanda Lopes Carvalho, Livia Bassani Lins de Miranda, Bruna Oliveira de Almeida, Keli Lima, João Agostinho Machado-Neto
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
Yixuan Guo, Zhaoyun Liu, Lixiang Duan, Hongli Shen, Kai Ding, Rong Fu
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers
Hui K. Gan, Sagun Parakh, F. T. Lee, Niall C. Tebbutt, Malaka Ameratunga, Sze Ting Lee, Graeme J. O’Keefe, Sylvia J. Gong, Christine Vanrenen, Jaren Caine, Mara Giovannetti, Carmel Murone, Fiona E. Scott, Nancy Guo, Ingrid J. G. Burvenich, Cameron Paine, Mary J. Macri, Masakatsu Kotsuma, Giorgio Senaldi, Ralph Venhaus, Andrew M. Scott
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects
Ming-min Cai, Ting Dou, Lu Tang, Qiu-yue Sun, Zi-hong Zhai, Hui-ping Wang, Wei Qian
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
Patricia LoRusso, Mark J. Ratain, Toshihiko Doi, Drew W. Rasco, Maja J. A. de Jonge, Victor Moreno, Benedito A. Carneiro, Lot A. Devriese, Adam Petrich, Dimple Modi, Susan Morgan-Lappe, Silpa Nuthalapati, Monica Motwani, Martin Dunbar, Jaimee Glasgow, Bruno C. Medeiros, Emiliano Calvo
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia
Margaret T. Kasner, Molly B. Halloran, Jonathan Pan, Ellen K. Ritchie, Gerald J. Fetterly, Douglas Kramer, David G. Hangauer, James E. Thompson
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
Luke S McLean, Tessa A Morris, Ann Gramza, Stephen Liu, Saad A. Khan, A. Dimitrios Colevas, Tillman Pearce, Danny Rischin
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
Wen-Chi Wu, Tzu-Yuan Lin, Ming‑Huang Chen, Yi‑Ping Hung, Chien-An Liu, Rheun‑Chuan Lee, Yi‑Hsiang Huang, Yee Chao, San-Chi Chen
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
Daniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli, Aurelio Miracolo, Panos Kanavos
The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
Li-Fang Meng, Jian-Feng Huang, Peng-Hui Luo, Shang-Xiao Huang, Han-Lei Wang
Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients
Kangsong Tian, Wei Qi, Qian Yan, Ming Lv, Delei Song
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis
Yunxia Tao, Yu Zhou, Le Tang, Haizhu Chen, Yu Feng, Yuankai Shi
Practical consideration for successful sequential tumor biopsies in first-in-human trials
Takafumi Koyama, Toshio Shimizu, Jun Sato, Yuki Katsuya, Satoru Iwasa, Shunsuke Kondo, Tatsuya Yoshida, Kazuki Sudo, Makoto Nishino, Yuichi Takiguchi, Kan Yonemori, Noboru Yamamoto
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
Xiang Tian, Qiong Liao, Qidong Yang, Lin Chen, Mingzhe Xiao, Yuanjian Cheng
Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1
Yiming Tao, Jie Han, Yongsheng Li
Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma
Guanglin Shi, Yuyan Luo, Zhaonan Yu, Yue Wang, Bojin Zhu
Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis
Junlong Ma, Wenjing Chen, Zhanqing Hu, Jie Huang, Chengxian Guo, Chan Zou, Guoping Yang
Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas
Yingjun Zhang, C. H. Wong, Herbert H. F. Loong
A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment
Rui Jiang, Dongguang Wei, Yuan Tan, Qianqian Duan